In a 16-week, Phase II study of 60 patients with active acromegaly, biochemical control of GH and IGF-1 levels was achieved by 27 % of patients after 12 weeks of treatment with subcutaneous (sc) pasireotide, and 39 % of patients achieved significant (≥20 %) tumor volume reduction [12]. This evidence concerns the gene GH1 and neoplasm.